Printer Friendly

Cardionovum commences clinical study of Aperto drug coated balloon.

Cardionovum GmbH has begun a 150-patient clinical study of its paclitaxel-releasing, high-pressure shunt balloon dilatation catheter, Aperto. The study aims to sustain the first clinical evidence for the product.

Regardless of whether it is created as an arterio-venous fistula or as a shunt graft, hemodialysis shunt patency is threatened by restenosis--the leading cause of hemodialysis shunt failure and a complication in the treatment of hemodialysis-dependent, end-stage renal disease patients. Shortcutting the arterial and venous vascular system to create a hemodialysis shunt results in hemodynamic pressure and blood flow gradients that are crucial to enable hemodialysis but which induce as a downside the formation of neo-intimal hyperplasia and stenosis. Experts believe the suppression of neo-intimal hyperplasia is a logical way to lower the frequency of necessary shunt interventions and prolong overall hemodialysis shunt patency.

Hemodialysis shunt stenosis treatment with Cardionovum's Aperto paclitaxel-releasing, high-pressure balloon dilatation catheter adds an anti-inflammatory and anti-proliferative therapeutic effect to the conventional, purely mechanical angioplasty procedure, which--despite being ineffective in restenosis prevention--currently is widely used to treat hemodialysis vessel stenosis, the company claims.

"The application of Aperto promises a substantial reduction of hemodialysis shunt restenosis for a prolonged dialysis access survival. This means less shunt reinterventions for a better patient life quality," said William Loan, M.D., principal study investigator at the National Vascular Hospital in Belfast, Ireland.

Aperto's drug coating is designed to treat the complex restenotic and scarred hemodialysis shunt tissue. Cardionovum bigwigs believe it has the potential to replace the conventional angioplasty procedure, whose mode of action catalyzes excessive mechanical stress with consecutive disruption of the vessel intima and media, as well as tension on the adventitia. The treatment triggers the migration and proliferation of fibroblasts, myofibroblasts, and smooth muscle cells, and further contributes to the development of consecutive neo-intimal hyperplasia.

Early clinical data with the Aperto drug-coated balloon have shown that the negative cycle of repeated, purely mechanical shunt treatments are reduced significantly.

Based in Bonn, Germany, Cardionovum develops drug-eluting stents/drug-eluting balloon technologies to treat coronary and vascular artery disease.

COPYRIGHT 2015 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Top of the News
Publication:Medical Product Outsourcing
Article Type:Clinical report
Date:Apr 1, 2015
Previous Article:Medovex Corp. acquires Streamline Inc.
Next Article:Zimmer-Biomet deal receives European Commission OK.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters